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Background: The use of ﬁne needle biopsy (FNB) for the diagnosis of metastatic melanoma
can lead to the early removal and treatment of metastases, reduce the frequency of unnecessary
surgery, and facilitate the staging of patients enrolled in clinical trials of adjuvant therapies. In
this study, the accuracy of FNB for the diagnosis of metastatic melanoma was investigated.
Methods: A retrospective cohort study was performed with 2204 consecutive FNBs per-
formed on 1416 patients known or suspected to have metastatic melanoma. Almost three-
quarters (1582) of these FNBs were veriﬁed by either histopathologic diagnosis following sur-




the specimen by a cytopathologist who had reported >500 cases, lesions located in the skin and
subcutis, and patients with ulcerated primary melanomas were factors associated with a sig-
niﬁcant improvement in the sensitivity of the test. However, FNBs performed in masses located
inlymphnodesoftheaxillaandFNBsthatrequiredmorethanoneneedlepasstoobtainasample
were far more likely to result in false-negative results.
Conclusions: FNB is a rapid, accurate, and clinically useful technique for the assessment of
disease status in patients with suspected metastatic melanoma.
Key Words: Cytology—Diagnosis—Diagnostic accuracy—Fine needle biopsy—Melanoma—
Pathology.
Fine needle biopsy (FNB) is frequently used in the
diagnostic workup of clinically or radiologically
detected mass lesions that are suspicious for meta-
static melanoma. By determining whether they rep-
resent metastatic melanoma, the use of FNB in
melanoma patients can expedite detection of
metastases, leading to earlier removal and treatment;
facilitate the staging of patients enrolled in clinical
trials of adjuvant therapies (particularly in deep-se-
ated lesions); reduce the frequency of unnecessary
surgery; and assist in the planning of the most
appropriate surgery.
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323FNB is a swift, minimally invasive and cost-eﬀec-
tive technique employed in the diagnostic workup of
mass lesions occurring in a wide variety of organs.
1,2
The technique has been extensively evaluated in
assessing the nature of lesions located in the tissues of
the breast, thyroid, lung, liver, pancreas, lymph
nodes, salivary glands, and kidneys, among other
locations.
3–6
There have been several previous case studies
assessing the use of FNB in patients with melanoma.
The majority of these studies lacked suﬃcient case
numbers to precisely determine the diagnostic accu-
racy of FNB.
7–10 However, in 1986, Perry and col-
leagues
11 analyzed almost 300 FNBs from melanoma
patients and found the procedure to be accurate, with
a sensitivity of 86.5% and a speciﬁcity of 96.1%. Since
this study, there have been important changes in the
procedure, including improvements in immuno-
chemical characterization and radiological guidance.
In 2000, Voit and colleagues
12 published a study of
739 FNBs from melanoma patients with palpable
suspicious lymph nodes or small lesions that were
only detectable by ultrasound B-scan examination.
Although the authors reported a sensitivity of 97.8%
and a speciﬁcity of 100.0%, the sensitivity depended
on lesion size.
The objective of this retrospective cohort study was
to evaluate the diagnostic accuracy of the FNB pro-
cedure in the detection of metastatic melanoma. To
accomplish this, a very large consecutive sample was
collected of FNBs performed on melanoma patients
who attended the Sydney Melanoma Unit (SMU),
Sydney, Australia. This large sample also allowed
evaluation of the eﬀect of several clinicopathologic
features and factors related to the procedure on the
diagnostic accuracy of FNB.
MATERIALS AND METHODS
Patients
For all patients with melanoma who attended the
SMU and gave informed consent, clinical and histo-
logic details of their disease were recorded on the
SMU database, and follow-up information was en-
tered prospectively. Patients with suspicious clinically
palpable or radiologically identiﬁed mass lesions,
detected by a variety of imaging modalities, were
further investigated by FNB. All SMU patients who
underwent an FNB that had been reported by cyt-
opathologists from the Department of Anatomical
Pathology at the Royal Prince Alfred Hospital in
Sydney, Australia, between January 1992 and
December 2002 were identiﬁed from the SMU data-
base, and their clinical records and FNB reports were
reviewed. Details of the patients are provided in
Table 1.
FNB Procedure
For palpable lesions, the FNBs were performed by
the reporting cytopathologist or a trainee pathologist
under their supervision. Following localization and
stabilization of the lesion with one hand, a hollow
bore needle (22G, 23G, or 25G) was inserted directly
into the mass and the needle was moved swiftly in
and out for approximately 10 seconds. Aspiration
with a syringe was not used in the vast majority of
cases, hence our preference for the term ﬁne needle
biopsy and ‘ﬁne needle aspiration biopsy. In our
experience, the use of a needle without an attached
syringe allows better control of the movement of the
needle. Furthermore, aspiration often yields blood,
promotes clotting and hampers optimal interpreta-
tion of cytologic detail. The procured material was
ejected from the needle onto glass slides by pushing
air from a syringe through the needle. The material
was spread evenly across the slide using another glass
slide. One slide was air-dried and stained immediately
with Diﬀ-Quik (Lab Aids, Narrabeen, NSW, Aus-















Other cancer diagnoses 159 11.2
More than one other cancer diagnoses 15 1.1









Total no. of patients 1416 100.0
FNB, ﬁne needle aspiration biopsy.
A. DOUBROVSKY ET AL. 324
Ann. Surg. Oncol. Vol. 15, No. 1, 2008tralia) and another ﬁxed in alcohol and later stained
by the Papanicolaou method.
2 Residual material was
washed into Hanks balanced salt solution for later
preparation of cell blocks using the serum-pro-
thrombin method
2 or by cytocentrifuge preparations,
to be used for immunochemistry. The air-dried slides
were examined by the cytopathologist at the time of
the procedure. Further passes were performed if
necessary, depending on the amount and type of
cellular material obtained.
Review of Clinical Material and Follow-up
The accuracy of the FNB procedure in diagnosing
metastatic melanoma was evaluated by two reference
standards: a) histopathologic evaluation of the ex-
cised lesion (1120 cases) or b) follow-up in those cases
for which histologic material was not available (462
cases). The duration of follow-up was 6 months or
greater (mean 50.2 months, median 45.7 months,
range 6.1–144.4 months) in 456 cases. In six cases, the
length of follow-up was less than 6 months (mean 4.2
months, median 4.0 months, range 3.0–5.7 months).
The mass was considered benign if it was stable in size
or resolved after clinical follow-up.
Cytodiagnosis
Cytodiagnoses were categorized as positive, suspi-
cious, or negative for metastatic melanoma (Table 2).
Cases were considered positive for metastatic mela-
noma if the specimen included sufﬁcient numbers of
well-preserved malignant cells with typical cytological
features, pigment, and/or conﬁrmatory immuno-
chemistry for a conﬁdent diagnosis of melanoma to
be made. On veriﬁcation, these samples were classi-
ﬁed as truly positive (n = 800, 50.5%) or falsely
positive (n = 5, 0.3%).
Samples that contained cells from unclassiﬁed/
unspeciﬁed malignancies or cases categorized as sus-
picious for melanoma (those with small numbers of
atypical cells, poorly preserved cells, and cells that
lacked speciﬁc features of melanoma, such as cyto-
plasmic pigment, and where insuﬃcient material was
present for immunochemistry) were classiﬁed as sus-
picious for metastatic melanoma. These were deter-
mined to be true suspicious (n = 78, 4.9%) or falsely
suspicious (n = 18, 1.1%) results after veriﬁcation.
FNBs classiﬁed as negative for metastatic mela-
noma contained no material that could be diagnosed
as metastatic melanoma. They included cases con-
taining malignant cells diagnosed as another neo-
plasm or b) various amounts of cellular material from
the tissue of the site that was sampled. After veriﬁ-
cation, these procedures were found to be either true
negative (n = 612, 38.7%) or false negative (n = 69,
4.4%).
Statistical Analysis
All analyses were performed using the S-PLUS
software package (Insightful Corporation, Seattle,
WA) and Microsoft Excel, version 2000 (Microsoft,
Redmond, WA). Diagnostic accuracy of FNB for
metastatic melanoma was measured by the sensitivity
and speciﬁcity of the test.
The eﬀect of the type of tissue involved by mela-
noma, anatomic location, and 15 clinicopathologic
and procedural factors were analyzed. These factors
included features of the primary melanoma such as
tumor thickness, dermal mitotic rate, presence of
ulceration, predominant cell type and histopathologic
subtype of melanoma; patient attributes such as sex,
American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) stage,
13
age at FNB and location of the FNB (local or distant
to the primary lesion); aspects of the FNB procedure
TABLE 2. Categories of cytodiagnoses
Characteristic Total n % Conﬁrmed Not conﬁrmed
Positive for Metastatic Melanoma
Malignant cells—melanoma 1089 49.4 805 284
Suspicious for Metastatic Melanoma
Malignant cells—suspicious for melanoma 44 2.0 39 5
Malignant cells—unknown cancer 33 1.5 22 11
Suspicious for malignancy 40 1.8 35 5
Negative for Metastatic Melanoma
Malignant cells—other cancer 92 4.2 47 45
No malignant cells—other cells present 416 18.9 308 108
No malignant cells—scant other cells 296 13.4 204 92
No malignant cells—no other cells 175 7.9 122 53
No malignant cells—procedure not performed 19 0.9 0 19
Total 2204 100 1582 622
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experience (based on caseload) of the reporting
cytopathologist; year of procedure, use of immuno-
stains; and presence of necrosis. Statistical signiﬁ-
cance was determined by the 95% conﬁdence intervals
(95% CIs) of these parameters. When comparing
different samples, a two-sample test for binomial




In the 11-year study period, 2204 consecutive
FNBs were performed in 1416 patients. Nineteen
FNBs (0.9% of all FNB cases) were excluded from
the analysis because the procedure could not be
performed, i.e., no aspirate was obtained (Table 3).
In half of these cases, the lesion could not be located
(inappropriate referrals), but patient pain tolerance
and difﬁculties with the procedure also contributed.
Veriﬁcation of the remaining 2185 FNBs was par-
tial; in 1582 (71.8%), the true disease status was
conﬁrmable by either histopathologic evaluation of
the excised lesion or by clinical follow-up (Fig. 1). A
total of 1120 FNBs were veriﬁed by histopathologic
evaluation of the excised lesion; all conﬁrmed positive
FNBs and FNBs with false-positive or negative re-
sults were veriﬁed histologically. In those cases
(mostly FNBs with negative results) where histopa-
thologic material was not available (462 cases), veri-
ﬁcation was made by clinical follow-up. The mass
was considered benign if it was stable in size or if it
resolved after clinical follow-up. The duration of
follow-up was >6 months in 456 cases and 3 to 6
months in 6 cases. Of the veriﬁed FNBs, 1435 (90.7%)
were palpation-guided FNBs performed by trainee
cytopathologists or cytopathologists, while 147
(9.3%) were image-guided FNBs performed by radi-
ologists or other physicians.
A total of 603 FNBs (27.4%) could not be veriﬁed;
this was due to loss to follow-up, particularly by
death in patients with advanced metastatic mela-
noma, uncertainty regarding sites (where FNBs from
more than one site were obtained at the same visit to
the clinic), and where there were multiple metastases,
which led to uncertainty in lesion location and the
correlation of FNB and histopathologic results.
Unconﬁrmed FNBs diﬀered from conﬁrmed proce-
dures in several ways. They were more likely to be
from lesions located in visceral organs or to be in
patients with AJCC/UICC stage IV disease. FNBs
with inconclusive cytodiagnoses were more likely to
be followed up with clinical observation or further
biopsy.
Conﬁrmation of FNBs was unaﬀected by the year
of procedure, the number of needle passes during
sampling, the use of immunostains, the reporting
cytopathologist, or the age or sex of the patient.
Approximately 12% of the patients were diagnosed
with additional cancers (most commonly breast can-
cer, colorectal cancer, and chronic lymphocytic leu-
kaemia), with some suﬀering from multiple types of
other cancers. Multiple primary melanomas occurred
TABLE 3. Fine needle biopsy procedures that could not be performed
Location Explanation for failure Conﬁrmation Histology
Left neck Unable to locate lesion Negative—follow-up –
Left face (subcutis) Pain Not conﬁrmed –
Right face Unable to locate lesion Not conﬁrmed –
Left neck (LN) Unable to locate lesion Negative—surgery No evidence of malignancy
Right breast Adjacent to prothesis Negative—follow-up –
Right neck Pain Not conﬁrmed –
Right axilla (LN) Unable to locate lesion Negative—follow-up –
Right neck Pain Negative—surgery No evidence of malignancy
Left neck (LN) Pain Negative—follow-up –
Left neck (LN) Unable to locate lesion Negative—follow-up –
Right groin Pain Negative—surgery No evidence of malignancy
Left axilla (LN) Unable to locate lesion Positive—surgery Melanoma
Right axilla (LN) Unable to locate lesion Negative—follow-up –
Right neck (LN) Pain Not conﬁrmed –
Left axilla (LN) Unable to locate lesion Not conﬁrmed –
Left neck Unable to locate lesion Negative—follow-up –
Thyroid Unable to locate lesion Negative—follow-up –
Right axilla (LN) Unable to locate lesion Negative—follow-up –
Right sternum (LN) Unable to locate lesion Not conﬁrmed –
LN, lymph node.
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of the patients underwent multiple FNBs. These
procedures were performed both concurrently and
sequentially.
There were 1582 FNB procedures for metastatic
melanoma with histologic veriﬁcation or clinical fol-
low-up. The overall sensitivity was 92.1% (95% CI,
93.7–90.0) and the specificity was 99.2% (95% CI,
99.7–98.1). Five cases were determined to be false
positive, resulting in a false-positive rate of 0.6%
(Table 4). The false-negative rate was 10.2%, with no
metastatic melanoma identiﬁed in 69 FNB cases in
which metastatic melanoma was identiﬁed by later
histologic evaluation (Fig. 2).
The large numbers of conﬁrmed cases permitted
detailed analysis of this procedure for metastatic
melanoma. The eﬀect of FNB site was studied (Ta-
ble 5). Lymph node tissue was the most common site
for FNB evaluation, with 926 procedures, 753 of
them conﬁrmed. The sensitivity and speciﬁcity of
FNB for metastatic melanoma in lymph nodes were
not signiﬁcantly different compared with that for all
sites. However, the sensitivity for FNBs performed
on lymph nodes located in the axilla was approxi-
mately 9% less compared with FNBs performed on
lymph nodes in other locations (z = )3.9, P =
0.0001). Increased FNB sensitivity (by 4%) was found
when the procedure was performed on lesions located
in the skin and subcutis compared with other sites.
However, this was only of borderline signiﬁcance
(z = 1.9, P = 0.05). Too few conﬁrmed FNBs were
conducted on visceral organs (n = 79) to allow
conclusions to be drawn regarding the success of the
procedure in these locations.
Fifteen clinicopathologic and procedural factors
were analyzed to assess their eﬀect on the diagnostic
accuracy of FNB for metastatic melanoma (Table 6).









800 (50.5%) True Positive 
100% confirmed by surgery 
69 (4.4%) False Negative 
100% confirmed by surgery 
5 (0.3%) False Positive 
100% confirmed by surgery 
612 (38.7%) True Negative 
25.0% confirmed by surgery 
75.0% confirmed by clinical follow up 
18 (1.1%) False Suspicious 
88.9% confirmed by surgery 
11.1% confirmed by clinical follow up 
78 (4.9%) True Suspicious 





FIG. 1. Flow diagram showing ﬁne needle
biopsy (FNB) result distribution.
TABLE 4. False-positive ﬁne needle biopsy ﬁndings for metastatic melanoma
Cytodiagnosis Histology Location Comment
Melanoma Metastatic adenocarcinoma Right axillary (LN) –
Melanoma Metastatic papillary carcinoma Left supraclavicular fossa (LN) –
Melanoma Hematoma Left axilla –
Melanoma Chronic osteomyelitis Left skull (bone) S100 positive
a
Melanoma Metastatic adenocarcinoma Right axilla –
LN, lymph node.
aS100-positive histiocytes were identiﬁed in the excision specimen, which probably caused the misdiagnosis.
69 False Negative FNBs 
(identified as no 
malignant cells 
observed) 
26 contained other cellular 
material 
22 contained only scant 
cellular material 
21 contained no cellular 
material 
FIG. 2. Distribution of false-negative ﬁne needle biopsy (FNB)
cytodiagnoses.
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copathologic factors, with the exception of AJCC/
UICC stage and location (distant or regional to the
primary lesion), as described above.
Patients with an ulcerated primary lesion experi-
enced slightly better FNB test sensitivity compared to
those with no ulceration (z = 1.9, P = 0.05). AJCC/
UICC stage, anatomic location, year of procedure,
needle size, sex, age at FNB, primary lesion thickness,
dermal mitotic rate, predominant cell type, histologic
subtype of melanoma, and presence of necrosis did
not aﬀect the diagnostic accuracy of the test (Table 6).
Three factors related to the conduct of the proce-
dure aﬀected FNB test accuracy. These were the
number of needle passes needed to collect the sample,
the number of FNBs for metastatic melanoma the
cytopathologist had reported during the study period
(caseload), and the use of immunostains. Samples
that required only one attempt at FNB had a sensi-
tivity increase by >10% compared to samples with
more than one attempt (z = 4.8, P < 0.001). Sensi-
tivity fell in a linear manner with each subsequent
attempt (Fig. 3). Cytopathologists who had caseloads
of >500 FNBs (2 cytopathologists) had greater FNB
test sensitivity by about 5% compared to those who
had reported <500 FNBs (16 cytopathologists) (z =
2.4, P = 0.02). Finally, FNB tests in which immu-
nostains were used had better sensitivity (z = 4.8, P
<0.001) (Table 6).
DISCUSSION
Metastatic melanoma is an aggressive tumor with a
high mortality rate. Patients with primary melanomas
that are at high risk of metastasizing who attend the
SMU are followed closely for evidence of metastatic
disease with radiological investigations and regular
clinical follow-up. Early surgery for metastatic dis-
ease may lead to longer disease-free periods and may
ultimately improve survival in some of these patients.
This underscores the importance of early detection of
metastatic disease.
In some melanoma treatment centers, FNB has
been used for many years to verify clinically suspi-
cious lesions and radiological abnormalities in pa-
tients with melanoma, prior to traumatic or costly
surgical or adjuvant treatment. FNB is a cost-eﬀec-
tive, rapid procedure that is well tolerated by patients
when performed by proﬁcient operators.
2 However,
the ability of the test to accurately diagnose suspi-
cious lesions as metastatic melanoma has been
infrequently studied.
Sensitivity and speciﬁcity are measures that are
used extensively in the FNB literature. They were
chosen as the best measures of diagnostic accuracy of
FNBs in patients with melanoma because of the
binary quality of the data.
16 In this study, a large
number of consecutive FNB procedures (2204) for
metastatic melanoma were analyzed, with 1582 pro-
cedures conﬁrmed by either histopathology after
surgical resection or by clinical follow-up. This co-
hort represents more FNB procedures in melanoma
patients than all previous reported series com-
bined.
7–12 The overall sensitivity of FNB for meta-
static melanoma was 92.1%, and the speciﬁcity was
99.2%. These results are superior to those obtained
by Perry and colleagues
11 in their study of 298 (261
conﬁrmed) cases of metastatic melanoma FNB more
than 20 years ago (sensitivity of 86.5% and speciﬁcity
TABLE 5. Diagnostic accuracy of FNB: Effect of tissue type and anatomic location
Location n Conﬁrmed % TP FN TS FS FP TN Sn (95% CI) Sp (95% CI)
All FNB 2204 1582 71.8 800 69 78 18 5 612 0.92 (0.90–0.94) 0.99 (0.98–1.00)
Lymph nodes 926 753 81.3 413 43 41 7 3 246 0.91 (0.88–0.93) 0.99 (0.97–1.00)
Neck 235 185 78.7 104 3 15 4 1 58 0.97 (0.92–0.99) 0.98 (0.91–1.00)
Axilla 383 313 81.7 155 29 12 2 2 113 0.84
a (0.78–0.89) 0.98 (0.94–1.00)
Groin 274 233 85.0 144 11 11 0 0 67 0.93 (0.88–0.96) 1.00 –
Other 34 22 64.7 10 0 3 1 0 8 1.00 – 1.00 –
Skin and subcutis 711 504 70.9 270 17 26 4 0 187 0.94
b (0.91–0.96) 1.00 –
Head and neck 131 98 74.8 54 5 7 0 0 32 0.92 (0.82–0.96) 1.00 –
Trunk 288 196 68.1 101 4 6 2 0 83 0.96 (0.91–0.99) 1.00 –
Limbs 292 210 71.9 115 8 13 2 0 72 0.93 (0.88–0.97) 1.00 –
Visceral organs 176 79 44.9 30 3 5 2 0 39 0.91 (0.76–0.97) 1.00 –
Liver 56 22 39.3 7 1 1 0 0 13 0.88 (0.53–0.98) 1.00 –
Lung 94 43 45.7 18 2 4 1 0 18 0.90 (0.70–0.97) 1.00 –
Other 391 246 62.9 87 6 6 5 2 140 0.94 (0.87–0.97) 0.99 (0.95–1.00)
TP, true positive; FN, false negative; TS, true suspicious; FN, false suspicious; FP, false positive; TN, true negative; SN, sensitivity; SP,
speciﬁcity; 95% CI, 95% conﬁdence interval.
aAxilla lymph nodes had signiﬁcantly reduced sensitivity compared with other sites (z = -3.9, P = .0001).
bSkin and subcutis FNBs had signiﬁcantly increased sensitivity compared with other sites (z = 1.9, P = .05).
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Factor N Conﬁrmed % TP FN TS FS FP TN SN (95% CI) SP (95% CI)
All FNB 2204 1582 71.8 800 69 78 18 5 612 0.92 (0.90–0.94) 0.99 (0.98–1.00)
AJCC/UICC stage at FNB
Stage I 400 323 80.8 128 9 22 6 3 155 0.93 (0.88–0.97) 0.98 (0.95–0.99)
Stage II 705 569 80.7 283 31 24 6 1 224 0.90 (0.86–0.93) 1.00 (0.98–1.00)
Stage III 836 561 67.1 310 24 27 5 1 194 0.93 (0.90–0.95) 0.99 (0.97–1.00)
Stage IV 263 129 49.0 79 5 5 1 0 39 0.94 (0.87–0.97) 1.00 (0.91–1.00)
Location
Regional 1340 1077 80.4 617 58 58 6 4 334 0.91 (0.89–0.93) 0.99 (0.97–1.00)
Distant 864 505 58.4 183 11 20 12 1 278 0.94 (0.90–0.97) 1.00 (0.98–1.00)
Use of immunochemistry
Yes 583 406 69.6 316 6 26 8 1 49 0.98
a (0.96–0.99) 0.98 (0.90–1.00)
No 1621 1176 72.5 484 63 52 10 4 563 0.88 (0.86–0.91) 0.99 (0.98–1.00)
Year
1992–1994 392 285 72.7 144 15 15 5 1 105 0.91 (0.85–0.94) 0.99 (0.95–1.00)
1995–1997 555 414 74.6 216 15 13 6 1 163 0.94 (0.90–0.96) 0.99 (0.97–1.00)
1998–2000 693 500 72.2 241 21 26 3 2 207 0.92 (0.88–0.95) 0.99 (0.97–1.00)
2001–2002 564 383 67.9 199 18 24 4 1 137 0.92 (0.87–0.95) 0.99 (0.96–1.00)
Sex
Male 1370 994 72.6 500 48 45 10 1 390 0.91 (0.89–0.93) 1.00 (0.99–1.00)
Female 834 588 70.5 300 21 33 8 4 222 0.93 (0.90–0.96) 0.98 (0.96–0.99)
Age at FNB
£50 y 572 414 72.4 198 12 22 1 2 179 0.94 (0.90–0.97) 0.99 (0.96–1.00)
>50 y 1632 1168 71.6 602 57 56 17 3 433 0.91 (0.89–0.93) 0.99 (0.98–1.00)
No. of FNB attempts
1 426 309 72.5 232 4 3 2 0 68 0.98
b (0.96–0.99) 1.00 (0.95–1.00)
2 518 371 71.6 185 13 21 3 0 149 0.93 (0.89–0.96) 1.00 (0.97–1.00)
3 315 219 69.5 79 13 12 6 0 109 0.86 (0.77–0.92) 1.00 (0.97–1.00)
‡4 192 136 70.8 33 17 21 1 1 63 0.66 (0.52–0.78) 0.98 (0.92–1.00)
Unknown 753 547 72.6 271 22 21 6 4 223 0.92 (0.89–0.95) 0.98 (0.96–0.99)
Needle size
c
22G 133 60 45.1 22 2 4 1 0 31 0.92 (0.74–0.98) 1.00 (0.89–1.00)
23G 173 138 79.8 66 7 8 2 0 55 0.90 (0.81–0.95) 1.00 (0.93–1.00)
25G 910 664 73.0 351 24 39 7 1 242 0.94 (0.91–0.96) 1.00 (0.98–1.00)
Necrosis present
Yes 67 41 61.2 24 4 9 0 0 4 0.86 (0.69–0.94) 1.00 (0.51–1.00)
No 2137 1541 72.1 776 65 69 18 5 608 0.92 (0.90–0.94) 0.99 (0.98–1.00)
Pathologist caseload
<100 cases 164 104 63.4 51 7 5 4 0 37 0.88 (0.77–0.94) 1.00 (0.91–1.00)
100–500 cases 651 474 72.8 227 29 27 3 2 186 0.89 (0.84–0.92) 0.99 (0.96–1.00)
>500 cases 1389 1004 72.3 522 33 46 11 3 389 0.94
d (0.92–0.96) 0.99 (0.08–1.00)
First primary Breslow thickness
£2 mm 950 705 74.2 332 23 34 8 4 304 0.94 (0.90–0.96) 0.99 (0.97–0.99)
>2 mm 919 662 72.0 367 38 33 6 0 218 0.91 (0.87–0.93) 1.00 (0.98–1.00)
Unknown 335 215 64.2 101 8 11 4 1 90 0.93 (0.86–0.96) 0.99 (0.94–1.00)
First primary ulceration
Yes 571 407 71.3 247 16 18 1 0 125 0.94
e (0.90–0.96) 1.00 (0.97–1.00)
No 1009 757 75.0 360 40 35 10 4 308 0.90 (0.87–0.93) 0.99 (0.97–1.00)
Unknown 624 418 67.0 193 13 25 7 1 179 0.94 (0.90–0.96) 0.99 (0.97–1.00)
First primary lesion mitotic rate (/mm
2)
£1 414 300 72.5 136 10 12 4 2 136 0.93 (0.88–0.96) 0.99 (0.95–1.00)
1 to <4 481 352 73.2 170 19 20 2 1 140 0.90 (0.85–0.93) 0.99 (0.96–1.00)
4 to <8 332 237 71.4 141 7 8 1 0 80 0.95 (0.91–0.98) 1.00 (0.95–1.00)
‡8 392 296 75.5 175 22 14 4 0 81 0.89 (0.84–0.93) 1.00 (0.95–1.00)
Unknown 585 397 67.9 178 11 24 7 2 175 0.94 (0.90–0.97) 0.99 (0.96–1.00)
First primary lesion histologic subtype
Desmoplastic 130 97 74.6 42 6 6 3 0 40 0.88 (0.75–0.94) 1.00 (0.91–1.00)
SSM 512 370 72.3 168 10 22 4 1 165 0.94 (0.90–0.97) 0.99 (0.97–1.00)
NM 461 343 74.4 198 20 14 4 1 106 0.91 (0.86–0.94) 0.99 (0.95–1.00)
Other 754 549 72.8 277 26 22 4 1 219 0.91 (0.88–0.94) 1.00 (0.97–1.00)
Unknown 347 223 64.3 115 7 14 3 2 82 0.94 (0.89–0.97) 0.98 (0.92–0.99)
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power to determine the true diagnostic accuracy of
FNB because of their low numbers of FNBs (between
56 and 108 conﬁrmed cases).
7–10 Voit and col-
leagues
12 examined 739 FNBs for metastatic mela-
noma and found the technique to be highly sensitive
(97.9%) at their institution. However, regional node
basins in their patient population were routinely
evaluated by ultrasound B-scan, and a third of FNB
cases were performed under ultrasound guidance.
Studies of FNB are frequently retrospective inves-
tigations and thus veriﬁcation bias may be a hazard
in these studies. Not only are there diﬀerent reference
tests, which are determined by the results of the FNB
procedure, namely histopathology after surgical
resection for all positive FNB tests and clinical fol-
low-up for most negative procedures, but veriﬁcation
is also partial. Not every consecutive FNB can be
veriﬁed. Diﬀerential veriﬁcation can lead to overes-
timation of the measures of diagnostic accuracy.
17,18
This bias is related to the quality of the reference
tests. Conﬁrmation of melanoma metastases by hist-
opathologic examination of tissue removed after
surgery is better at identifying true disease status than
clinical follow-up of patients with negative FNB re-
sults.
19 Melanoma metastases may regress spontane-
ously, resulting in failure to identify all false-negative
results by clinical follow-up, or they may cause truly
positive ﬁndings to be incorrectly classiﬁed as false
positives if the lesion resolves before it is excised or
during follow-up.
20,21
In this study, there were diﬀerences in those FNBs
that were veriﬁed by the reference tests compared
with those that were not. Unconﬁrmed FNBs were
more often performed on nonpalpable lesions in vis-
ceral sites, and in patients with advanced disease.
Veriﬁcation rates of negative, positive, and suspicious
FNBs were 68.2%, 73.9%, and 82.1%, respectively.
Despite the high speciﬁcity rate, as a result of the
large number of conﬁrmed biopsy samples, ﬁve false-
positive ﬁndings were detected (Table 4). The cyto-
logic features of these cases have been reviewed in
more detail elsewhere.
22 In all cases, misinterpreta-
tion of the cellular material had occurred, three of
which were found to be adenocarcinoma. Two of
these represented metastatic breast adenocarcinoma
in axillary nodes, and one was a metastatic papillary
adenocarcinoma of renal origin. Two other false-
positive cases were caused by the misinterpretation of
large histiocytes or reactive ﬁbroblasts as metastatic
melanoma cells.
In 69 FNBs, no metastatic melanoma cells were
identiﬁed cytologically; however, the presence of
TABLE 6. Continued
Factor N Conﬁrmed % TP FN TS FS FP TN SN (95% CI) SP (95% CI)
First primary lesion predominant cell type
Epithelioid 443 329 74.3 185 17 13 4 0 110 0.92 (0.87–0.95) 1.00 (0.97–1.00)
Spindle 137 89 65.0 47 6 9 0 0 27 0.89 (0.77–0.95) 1.00 (0.88–1.00)
Mixed 173 111 64.2 58 6 8 3 0 36 0.91 (0.81–0.96) 1.00 (0.90–1.00)
Unknown 1451 1053 72.6 510 40 48 11 5 439 0.93 (0.90–0.95) 0.99 (0.97–1.00)
TP, true positive; FN, false negative; TS, true suspicious; FN, false negative; FP, false positive; TN, true negative; SN, sensitivity; SP,
speciﬁcity; 95% CI, 95% conﬁdence interval; SSM, superﬁcial spreading melanoma; NM, nodular melanoma.
aFNBs that used immunostains had signiﬁcantly increased sensitivity compared with those that did not (z = 4.8, P < .001).
bFNBs obtained in one pass had signiﬁcantly increased sensitivity compared with FNBs which required more than one pass (z = 4.8, P <
.001).
cThe size of the needle used for the FNB procedure was not known in 988 cases.
dFNBs reviewed by a cytopathologist who reported >500 cases had signiﬁcantly increased sensitivity compared with FNBs reported by
cytopathologists who had reported <500 cases (z = 2.4, P = .02).
eFNBs obtained from patients with an ulcerated ﬁrst primary lesion had increased sensitivity compared with FNBs from patients without
ulcerated ﬁrst primary lesions (z = 1.9, P = .05).


















Number of FNB attempts 
FIG. 3. Sensitivity of ﬁne needle biopsy (FNB) in the diagnosis of
metastatic melanoma. Sensitivity is reduced in a linear manner as
the number of FNB attempts needed to obtain the sample in-
creases. Bars, 95% conﬁdence intervals.
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histopathologic examination (false negatives)
(Fig. 2). Astute clinical and/or radiologic surveillance
results in the detection of small suspicious lymph
nodes. Difﬁculties in performing FNBs on such small
suspicious lymph nodes contribute to some of the
false-negative diagnoses (particulary small, mobile
axillary nodes). In fact, approximately a third (n =
21) of these biopsy samples (which were reported as
‘‘no malignant cells identiﬁed’’) did not contain any
cellular material, suggesting that an absence of sam-
pling of the malignant cells was the reason for the
false-negative result. Further investigation is usually
necessary to identify the cause of the mass lesion.
Surgical examination is usually the next step when the
index of clinical suspicion is high.
There were several sources of diﬃculty in per-
forming the FNB procedure for metastatic mela-
noma. Often it occurred when there was a failure to
locate the suspicious lesion because of its small size or
its location was not communicated with adequate
precision. Failure to identify metastatic melanoma
occurred when cellular material showed too few
typical morphologic characteristics of metastatic
melanoma, or these characteristics were destroyed or
masked by necrosis.
The large number of conﬁrmed FNB in this study
permitted the analysis of subgroups. Most FNB for
metastatic melanoma were performed in lymph nodes
as well as skin and subcutaneous tissues. No diﬀer-
ence in sensitivity was noted among these tissue
groups. However, FNBs of lymph nodes of the axilla
were signiﬁcantly less sensitive compared with those
performed at other sites and with FNBs performed in
lymph nodes of the groin and neck. A number of
factors are likely to contribute to the low sensitivity
of FNBs performed in the axilla, including the greater
diﬃculty in gaining access to and locating lymph
nodes, particularly those high in the axilla, and the
presence of large amounts of fatty tissue in axillary
lymph nodes (‘‘horseshoe’’ nodes).
Fifteen clinicopathologic factors were examined for
their eﬀect on the accuracy of FNB for metastatic
melanoma, most of which had no eﬀect on the
diagnostic accuracy of the test. However, the fol-
lowing four variables did inﬂuence the sensitivity of
the FNB procedure. (1) Ulceration of the primary
lesion led to a small increase in the sensitivity of the
test (P = 0.05). (2) Additional needle passes were
performed if the initial sampling failed to obtain
suﬃcient cellular material; thus, the number of needle
passes is an indicator of the diﬃculty in obtaining a
sample from a speciﬁc lesion. FNBs that were
performed in only one needle pass were found to have
superior sensitivity than those which required addi-
tional passes to obtain an adequate sample. Fur-
thermore, the sensitivity of the test seemed to
decrease in a linear manner with each subsequent
pass. (3) Training and experience have been shown to
signiﬁcantly inﬂuence the interpretation of FNB of
the breast,
23 and in this study, we found that the
caseload (i.e., level of experience) of the cytopathol-
ogist who reviewed the slides inﬂuenced the sensitiv-
ity of the test. Those cytopathologists who reviewed
>500 metastatic melanoma FNB samples in the
study period performed better. Those cytopatholo-
gists who performed <100 reviews seemed to do as
well as those who had a caseload of 100 to 500 cases.
(4) The use of immunostains was associated with
improved sensitivity of the test. However, this may
reﬂect the fact that immunochemistry was only per-
formed in those cases in which a sufﬁciently high
cellular yield was obtained, in which case it may have
been the high cellular yield that lead to an improve-
ment in sensitivity, rather than the use of immuno-
stains per se. The diverse cytological presentation of
metastatic melanoma may also be a factor in the
association of the use of immunochemistry with in-
creased sensitivity.
24,25 Nasiell et al.
26 found that
immunochemical characterization was necessary to
conclusively diagnose >50% of metastatic melano-
mas that presented with an equivocal cytological
picture. However, immunological characterization
cannot be considered deﬁnitive when the FNB lacks
typical cytologic features expected of metastatic
melanoma. For example, one of the false-positive
cases exhibited S100 positivity, whereas two of the
false-negative FNBs contained melanoma cells that
seemed to be S100 negative. This suggests that cyt-
opathologists should be cautious when reporting the
results of immunostains on limited samples.
Our study shows that FNB for metastatic mela-
noma is a procedure with very high speciﬁcity and
good sensitivity. Several clinicopathologic factors
were found to inﬂuence the diagnostic accuracy of the
test for metastatic melanoma. These included factors
relating to the original primary melanoma lesion,
location of the sampled lesion, and factors relating to
the performance of the test. The SMU employs an on-
demand FNB service with assessment of the cytologic
material and delivery of a provisional result to
the clinician at the time of the patients visit. This
helps guide subsequent diagnostic and therapeutic
measures, and it reduces costs (e.g., by decreasing the
need for additional patient visits to the clinic). A
multidisciplinary approach involving clinicians,
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and cost-eﬀective management strategy in melanoma
patients.
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